In vitro efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites
Vydyam P, Chand M, Gihaz S, Renard I, Heffernan G, Jacobus L, Jacobus D, Saionz K, Shah R, Shieh H, Terpinski J, Zhao W, Cornillot E, Mamoun C. In vitro efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites. Antimicrobial Agents And Chemotherapy 2024, 68: e00423-24. PMID: 39136469, PMCID: PMC11373198, DOI: 10.1128/aac.00423-24.Peer-Reviewed Original ResearchTherapeutic indexPlasmodium falciparum</i>Effective therapeutic strategyCausative agent of babesiosisIn vitro efficacyAntiparasitic drugsProtozoan parasitesMalaria parasitesIntraerythrocytic protozoan parasiteTherapeutic strategiesFolate pathwayBroad-spectrum antiparasitic drugStrain HB3Babesia divergensMalariaBabesia duncaniAnimal healthAntifolatesDrugWidespread resistanceCausative agentBiguanideBabesiaBabesiosisBiosynthesis of purinesA set of diagnostic tests for detection of active Babesia duncani infection
Chand M, Vydyam P, Pal A, Thekkiniath J, Darif D, Li Z, Choi J, Magni R, Luchini A, Tonnetti L, Horn E, Tufts D, Ben Mamoun C. A set of diagnostic tests for detection of active Babesia duncani infection. International Journal Of Infectious Diseases 2024, 147: 107178. PMID: 39025200, DOI: 10.1016/j.ijid.2024.107178.Peer-Reviewed Original ResearchB. microtiB. duncaniBlood samplesLife-threatening infectionsAntigen capture assayTick-borne diseasesFatal tick-borne diseaseP. falciparumBabesia genusScreening of blood samplesBabesia speciesB. divergensActive infectionAccurate diagnosisEffective disease managementPoint-of-care testingDiagnostic testsReservoir hostsBabesiaInfectionHuman babesiosisIntraerythrocytic parasitesImmunodominant antigensMolecular assaysCapture assay